Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza) in Subjects With Painful Knee Osteoarthritis

Trial Profile

A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Capsaicin Patch (Qutenza) in Subjects With Painful Knee Osteoarthritis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary) ; Capsaicin
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors Centrexion Therapeutics

Most Recent Events

  • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism.
  • 15 Jun 2019 Results (n=5) presented at the 20th Annual Congress of the European League Against Rheumatism.
  • 11 Jun 2019 According to a Centrexion Therapeutics media release, data from this trial will be presnetd at the 2019 European League Against Rheumatism (EULAR) Annual Conference taking place June 12-15, 2019 in Madrid, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top